The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).
 
Manmeet Singh Ahluwalia
Stock and Other Ownership Interests - doctible; MedInnovate Advisors LLC; MimiVax; TriSalus Life Sciences
Honoraria - Elsevier; Peerview; Prime Education; Prime Oncology
Consulting or Advisory Role - AlloVir; Anheart Therapeutics; Apollomics; Autem Therapeutics; Bayer; Bugworks; Cairn Therapeutics; Caris Life Sciences; Equillium; GlaxoSmithKline; InSightec; Janssen; Menarini Group; Modifi Bio; NH TherAguix; Nuvation Bio; Prelude Therapeutics; Pyramid Biosciences; SDP Oncology; Siemens Healhineers/Varian Medical Systems; Sumitomo Dainippon Pharma Oncology; ViewRay; Voyager Therapeutics; Xoft
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst); Seagen (Inst)
Other Relationship - Idorsia (I); ResMed (I)
 
David M. Peereboom
Honoraria - Novocure
Consulting or Advisory Role - Anheart Therapeutics; Neonc Technologies; Novocure; Orbus Therapeutics; SERVIER; Stemline Therapeutics
Research Funding - Apollomics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Global Coalition for Adaptive Research (Inst); Karyopharm Therapeutics (Inst); MimiVax (Inst); Neonc Technologies (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Vigeo Therapeutics (Inst)
Travel, Accommodations, Expenses - Novocure
Other Relationship - IN8bio (Inst)
 
Ahmad Ozair
No Relationships to Disclose
 
Atulya Aman Khosla
No Relationships to Disclose
 
Yasmeen Rauf
No Relationships to Disclose
 
Lakshmi Nayak
Honoraria - Ono Pharmaceutical
Consulting or Advisory Role - BraveBio; Genmab; Kite/Gilead; Ono Pharmaceutical
Speakers' Bureau - Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Kazia Therapeutics (Inst); Merck (Inst); Ono Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Wolters Kluwer/ UpToDate, Inc- Royalty
Travel, Accommodations, Expenses - Ono Pharmaceutical
 
Marci Ciolfi
No Relationships to Disclose
 
Tyler Alban
No Relationships to Disclose
 
Matthew Grabowski
No Relationships to Disclose
 
Pat Rayman
No Relationships to Disclose
 
Marcella Diaz
No Relationships to Disclose
 
Justin Lathia
No Relationships to Disclose
 
Eudocia Quant Lee
Honoraria - Medlink
Consulting or Advisory Role - Medscape
Patents, Royalties, Other Intellectual Property - Royalties from Wolter Kluwer for Up to Date, Inc
 
Patrick Y. Wen
Consulting or Advisory Role - Anheart Therapeutics; AstraZeneca; Bayer; Black Diamond Therapeutics; Boehringer Ingelheim; Celularity; Chimerix; Day One Biopharmaceuticals; Genenta Science; GlaxoSmithKline; Insightec; Kintara Therapeutics; Merck; Mundipharma; Mundipharma; Novartis; Novocure; Novocure; Prelude Therapeutics; Prelude Therapeutics; Sagimet Biosciences; Sapience Therapeutics; Servier; Servier; SymBio Pharmaceuticals; Tango Therapeutics; Telix Pharmaceuticals; VBI Vaccines
Research Funding - AstraZeneca (Inst); Bayer (Inst); Black Damond (Inst); Chimerix (Inst); Erasca, Inc (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Quadriga Biosciences (Inst); Servier (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
David A. Reardon
Stock and Other Ownership Interests - Anheart Therapeutics; Bionaut Labs
Honoraria - Advantagene; Agenus; Anheart Therapeutics; Avita Biomedical, Inc.; Bayer; Blue Rock Therapeutics; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CeCaVa; Chimeric Therapeutics; Deciphera; DelMar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Genentech/Roche; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kintara Therapeutics; KIYATEC; Medicenna; Merck; Merck KGaA; Monteris Medical; NEUVOGEN; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics; Sumitono Dainippon Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Vivacitas Oncology; Y-mAbs Therapeutics
Consulting or Advisory Role - Advantagene; Agenus; Agios; Anheart Therapeutics; Avita Biomedical; Bayer; Blue Rock Therapeutics; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CeCava; Chimeric Therapeutics; Deciphera; Delmar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Genentech/Roche; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kiyatec; Medicenna; Merck; Merck KGaA; NEUVOGEN; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics; Sumitomo Dainippon Pharma Oncology; Taiho Pharmaceutical; Vivacitas Oncology
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Asvattha Therapeutics (Inst); Celldex (Inst); EMD Serono (Inst); Enterome (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); InSightec (Inst); Merck (Inst); NeoTX (Inst); Novartis (Inst); Omniox